For our bio/pharma readers, we thought you would enjoy our latest Harness IP quarterly BioPharma Patents Newsletter. Click on the link to learn about the latest in: 1) Subject matter eligibility and “laws of nature”; 2) Unhelpful creativity in terminal disclaimers; and 3) Inter Partes Review of pharma patents.